Successes of the CDC monitoring systems in evaluating post-authorization safety of COVID-19 vaccines

Expert Rev Vaccines. 2022 Mar;21(3):281-284. doi: 10.1080/14760584.2022.2019020. Epub 2022 Jan 5.

Authors

Pedro L Moro¹, Michael M McNeil¹

Affiliation

¹ Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Zoonotic and Emerging Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

PMID: 34957900
DOI: 10.1080/14760584.2022.2019020

No abstract available

Keywords: Adverse events; COVID-19; SARS-CoV-2; adenovirus type 26; coronavirus; epidemiology; mRNA vaccines; surveillance; vaccine safety.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Centers for Disease Control and Prevention, U.S.
Humans
SARS-CoV-2
United States

Substances

COVID-19 Vaccines